Consumer Staples Sector Outperforms, ETF (XLP) Climbs 1.25%
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/28/2026
- S&P 500 ends lower; chips tumble and Moderna rallies
- SpaceX weighs Starlink mobile service to US consumers, FT reports
- U.S. chip stocks retreat after Apple price hikes stoke fears over AI trade
- Morgan Stanley flags Fed hike risk if unemployment drops below 4%
- UBS trims AI portfolio exposure to semis and hardware after recent rally
Johnson & Johnson's (JNJ) Potential to Change Multiple Myeloma Treatment Paradigm in Underappreciated, Stock Remains Top Pick - Cantor Fitzgerald
January 24, 2022 6:24 AM ESTCantor Fitzgerald analyst Louise Chen reiterated an Overweight rating and $215.00 price target on Johnson & Johnson (NYSE: JNJ) in light of the upcoming PDUFA for the company's CAR-T therapy.
The analyst quotes: "The PDUFA date for Johnson and Johnson (JNJ) and Legend Biotech's BCMA (B-cell... More
